122 related articles for article (PubMed ID: 21444917)
21. Long-term survival of a child with refractory anaplastic large cell lymphoma following therapy with an antisense oligonucleotide, topotecan, and vinblastine.
Wrobel G; Chaber R; Rygier J; Bonar J; Muszynska-Roslan K; Chybicka A
Hematol Oncol; 2015 Mar; 33(1):52-5. PubMed ID: 21809366
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
23. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
24. Ki-1 (CD30) anaplastic large-cell lymphoma in children.
Massimino M; Gasparini M; Giardini R
Ann Oncol; 1995 Nov; 6(9):915-20. PubMed ID: 8624295
[TBL] [Abstract][Full Text] [Related]
25. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
[TBL] [Abstract][Full Text] [Related]
26. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic large cell lymphoma: a single institution experience from India.
Lakshmaiah KC; Guruprasad B; Shah A; Kavitha S; Abraham LJ; Govindbabu K; Aruna Kumari BS; Appaji L
J Cancer Res Ther; 2013; 9(4):649-52. PubMed ID: 24518711
[TBL] [Abstract][Full Text] [Related]
28. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
Zinzani PL; Bendandi M; Martelli M; Falini B; Sabattini E; Amadori S; Gherlinzoni F; Martelli MF; Mandelli F; Tura S; Pileri SA
J Clin Oncol; 1996 Mar; 14(3):955-62. PubMed ID: 8622045
[TBL] [Abstract][Full Text] [Related]
29. Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.
Park SR; Baek JY; Kim DW; Im SA; Kim TY; Bang YJ; Kim NK; Jeon YK; Kim CW; Heo DS
J Korean Med Sci; 2006 Aug; 21(4):633-8. PubMed ID: 16891805
[TBL] [Abstract][Full Text] [Related]
30. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941.
Lowe EJ; Sposto R; Perkins SL; Gross TG; Finlay J; Zwick D; Abromowitch M;
Pediatr Blood Cancer; 2009 Mar; 52(3):335-9. PubMed ID: 18985718
[TBL] [Abstract][Full Text] [Related]
31. Clinical analysis of primary systemic anaplastic large cell lymphoma: a report of 57 cases.
Wang FH; Li YH; Zeng J; Rao HL; Xia ZJ; Sun XF; Huang HQ; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2009 Jan; 28(1):49-53. PubMed ID: 19448428
[TBL] [Abstract][Full Text] [Related]
32. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
Ait-Tahar K; Damm-Welk C; Burkhardt B; Zimmermann M; Klapper W; Reiter A; Pulford K; Woessmann W
Blood; 2010 Apr; 115(16):3314-9. PubMed ID: 20185586
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Factors and Treatment Outcome of Pediatric Anaplastic Large Cell Lymphoma Treated at the Children Cancer Hospital Egypt.
Abdel Rahman H; El Semary S; Sedky M; Atteya I; El Kinaaie N; El Wakeel M; Hassanein O; Mohy R
J Pediatr Hematol Oncol; 2019 Oct; 41(7):e427-e431. PubMed ID: 31343479
[TBL] [Abstract][Full Text] [Related]
34. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
35. [Diagnosis and treatment of large-cell anaplastic lymphoma in children].
Makhonova LA; Peterson IS; Tupitsyn NN; Slugin AI; Matveeva II; Kiselev AV
Vestn Ross Akad Med Nauk; 2000; (6):8-10. PubMed ID: 10943152
[TBL] [Abstract][Full Text] [Related]
36. [Ki-1+ large-cell anaplastic lymphoma with a leukemic appearance. Study of a case].
Rabasa P; Domingo JM; Quílez D; Monzón F
Sangre (Barc); 1998 Jun; 43(3):240-3. PubMed ID: 9741234
[TBL] [Abstract][Full Text] [Related]
37. Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood.
Pillon M; Gregucci F; Lombardi A; Santoro N; Piglione M; Sala A; D'Amore ES; De Santis R; Casale F; Zecca M; Mussolin L; Rosolen A;
Pediatr Blood Cancer; 2012 Nov; 59(5):828-33. PubMed ID: 22389307
[TBL] [Abstract][Full Text] [Related]
38. Primary CD30-positive anaplastic large cell lymphoma of the lip.
Chim CS; Chan AC; Raymond L
Oral Oncol; 1998 Jul; 34(4):313-5. PubMed ID: 9813729
[TBL] [Abstract][Full Text] [Related]
39. [High-dose polychemotherapy of patients with poor-prognosis anaplastic T.0-large cell ALK+ lymphosarcoma].
Aitova LG; Vinogradova IuE; Kaplanskaia IB; Lutsenko IN; Zvonkov EE; Momotiuk KS; Kravchenko SK; Kremenetskaia AM; Vorob'ev AI
Ter Arkh; 2009; 81(7):53-7. PubMed ID: 19708574
[TBL] [Abstract][Full Text] [Related]
40. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
